Guaranteed adherence.
Better outcomes.™

Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.

Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.

An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.

Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.
69%

Of patients do not adhere to their medication due to forgetfulness and inertia.

Our long-term solution for life-long conditions.

At Vivani we are developing our novel NanoPortal™ implant technology for delivering the intended dose of medication steadily over extended periods of time. It has been engineered with the goal of avoiding challenges that may be associated with fluctuating drug delivery.

Our Lead Drug Candidate: NPM-115

GLP-1 for Obesity

NPM-115 is a miniature, subdermal, high-dose exenatide drug implant designed to treat chronic weight management. This device can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.

Also Developing Candidate: NPM-119

GLP-1 for Type 2 Diabetes

NPM-119 is a miniature, six-month, subdermal, exenatide drug implant under development to treat patients with type 2 diabetes. We are currently preparing to initiate a First-in-Human study, also known as LIBERATE-1, in type 2 diabetes patients for a 12-week period.

News & Updates

05.13.24
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

 Read More  

05.09.24
Vivani Medical to Present at TIDES Conference 2024

 Read More  

03.26.24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year…

 Read More  

03.06.24
Vivani Medical Appoints Daniel Bradbury to its Board of Directors

 Read More  

03.01.24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common…

 Read More  

02.28.24
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy®…

 Read More  

11.14.23
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results

 Read More  

10.16.23
Vivani Medical to Present at BIO Investor Forum

 Read More  

09.07.23
Vivani Medical to Present at the Boulder Peptide Symposium

 Read More  

09.05.23
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The…

 Read More  

< >

Current Disease Targets of NanoPortal Platform Technology

Obesity

Type 2 Diabetes

Feline
Pre-Diabetes & Diabetes